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A review for Australian nurses: cannabis use for anti-emesis among
terminally ill patients in Australia
Abstract
Objective: The objective of this article is to describe the potential benefits of medicinal cannabis in emesis
control and the position of nurses looking after palliative patients who are on medicinal cannabis treatment in
Australia.
Setting; Palliative care
Primary argument: Cannabis is the most commonly abused drug and its use for medical purposes was
restricted throughout the world since the early 20th century. However many clinical studies show that the
natural cannabinoid compounds can stimulate the cannabinoid receptors in the brain leading to attenuation of
signal transmission, resulting in alleviation of the vomiting stimuli. The debate about the use of cannabis as an
anti-emetic agent in patients with life-limiting conditions has renewed interest in recent years. The principle of
palliative care is to improve the quality of life of patients living with life-limiting conditions based on the best
evidence available. Although some evidence suggests cannabis may have therapeutic effects on some palliative
patients and the Australian Commonwealth Government has recently changed the legislation, the concept of
using medicinal cannabis in emesis control is very new to many Australians including the health care
providers.
Conclusion: In comparison to conventional medications, medicinal use of cannabis in palliative care is a new
phenomenon and nurses as well as general public may be less prepared for the use of cannabis as a medical
modality in all clinical settings. This review is intended to raise awareness of the physiological mechanism of
cannabis and its medicinal use to the nurses in Australia.
Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences
Publication Details
Chan, A., Molloy, L., Pertile, J. & Iglesias, M. (2017). A review for Australian nurses: cannabis use for anti-
emesis among terminally ill patients in Australia. Australian Journal of Advanced Nursing, 34 (3), 43-47.
This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/4637
AUSTRALIAN JOURNAL OF ADVANCED NURSING Volume 34 Issue 3 43
SCHOLARLY PAPER
A review for Australian nurses: Cannabis use 
































Cannabis is the most commonly abused drug and its use for medical purposes was restricted throughout the 
world since the early 20th century. However many clinical studies show that the natural cannabinoid compounds 
can stimulate the cannabinoid receptors in the brain leading to attenuation of signal transmission, resulting in 
alleviation of the vomiting stimuli. The debate about the use of cannabis as an anti‑emetic agent in patients with 
life‑limiting conditions has renewed interest in recent years. The principle of palliative care is to improve the quality 
of life of patients living with life‑limiting conditions based on the best evidence available. Although some evidence 
suggests cannabis may have therapeutic effects on some palliative patients and the Australian Commonwealth 
Government has recently changed the legislation, the concept of using medicinal cannabis in emesis control is very 
new to many Australians including the health care providers.
Conclusion
In comparison to conventional medications, medicinal use of cannabis in palliative care is a new phenomenon and 
nurses as well as general public may be less prepared for the use of cannabis as a medical modality in all clinical 
settings. This review is intended to raise awareness of the physiological mechanism of cannabis and its medicinal 
use to the nurses in Australia. 




al 2013). In the early 20th century, there was a rise in its use for the euphoric effects. As a result, cannabis 
became a prohibited drug and its use for medical purposes was also restricted around the globe (Alexandre 
2011). However many clinical studies show that the natural cannabinoid compounds can stimulate the 
cannabinoid receptors in the brain leading to attenuation of signal transmission, resulting in alleviation of 
the	vomiting	stimuli	(Sharkey	et	al	2014;	Borgelt	et	al	2013;	Johannigman	and	Eschiti	2013).	The	debate	
about the use of cannabis for medical purposes has remerged in recent years. Currently, the use of synthetic 





provides an overview of the current legislation and the position of nurses caring for patients who decide to 
use medicinal cannabis in Australia. 
Method of review
The	literature	search	was	undertaken	in	three	electronic	databases;	PubMed,	CINAHL	and	MEDLINE	in	October	
2015. The various combinations of search terms cannabis, humans, vomiting, anti‑emetic agent, dronabinol, 
nabilone, cannabinoid receptors, medicinal cannabis, legislation, laws, Australia, palliative care and health care 
providers aimed to capture the articles in relation to the medicinal use of cannabis as an anti‑emetic agent. 
In addition, reference lists from the articles were also used to identify the relevant literature for this review. 
Effects of cannabis in humans
Emesis	is	a	complex	neurological	reflex	leading	to	ejection	of	possibly	poisonous	material	from	the	gastrointestinal	
tract, and nausea serves as an unconditioned stimulus to learn that the particular food should be avoided 
in	the	future	(Sharkey	et	al	2014).	Since	neural	control	of	nausea	and	emesis	uses	the	endocannabinoid	
system,	use	of	cannabis	as	an	antiemetic	could	be	justified	for	its	stimulation	of	the	endocannabinoid	system.	





and anandamide) leads to attenuation of signal transmission, resulting in alleviation of the vomiting stimuli 
(Sharkey	et	al	2014).	
It is through the stimulation of cannabinoid receptors in these areas that consumption of cannabis exerts its 





investigated for its antiemetic properties, but appears to potentiate the antiemetic properties of THC when 
administered	in	a	1:1	ratio	(Sharkey	et	al	2014).
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Nausea, as the sensation that precedes vomiting, is less well understood. Nausea centres reside in the 
forebrain,	but	activation	of	insular	cortex	during	nausea	links	this	area	to	the	vomiting	(Sharkey	et	al	2014).	
The	insular	cortex	contains	CB1	receptors	(Mackie	2005),	making	it	susceptible	to	the	inhibitory	effects	of	
endocannabinoids and plant‑derived cannabinoids, giving the latter the anti‑nausea properties.
While the above makes cannabis or its derivatives suitable antiemetic alternatives, the presence of cannabinoid 
receptors is not limited to the vomiting and nausea centres (Mackie 2005). Other neurological effects of 
cannabis use are mild euphoria, sedation, relaxation, hunger and sensory input enhancement, making it a 
drug for ‘recreational use’, despite other non‑desirable effects such as impaired attention, balance, cognition, 
judgement,	memory	and	sense	of	time,	as	well	as	anxiety,	disorientation,	paranoia	and	psychosis	(Borgelt	et	
al	2013).	These	effects	reflect	the	widespread	presence	of	cannabinoid	receptors	in	the	brain,	making	all	of	
them susceptible of stimulation by externally supplied cannabinoids. 
Despite	these	undesirable	effects,	there	is	potential	use	of	cannabis	use	in	a	medical	context,	specifically	
in palliative patients suffering from chronic terminal illnesses. While cannabis can cause addiction, it is 
ranked less addictive than tobacco, alcohol and another antiemetic drug also used for recreational purposes, 
ketamine (Nutt et al 2007). Furthermore, the physical harm caused by cannabis, both acute and chronic, is 
also	ranked	below	these	three	substances	(Nutt	et	al	2007).	The	benefit	of	nausea	and	emesis	suppression	
in the late stages of life may outweigh the risk of addiction or psychosis.
It is important to note that the active cannabinoids concentration may vary up to three‑fold in different strains 
(Borgelt	et	al	2013;	Barni‑Comparini	et	al	1984).	Therefore,	determining	the	dose	and	route	of	administration	
can pose several problems. To add complexity, the route of administration determines both absorption time, 
from a few minutes for smoked THC, to 30 minutes for oral THC. In addition, the bioavailability ranges from 
2‑56% for smoked THC and 5‑20% for oral THC with a peak concentration reached anywhere between one and 
three hours after ingestion (Huestis 2007). The two variables of quality and route administration make titration 
very	difficult	 in	 individual	patients,	when	also	considering	the	possible	co‑morbidities	such	as	respiratory	
deficiencies	that	would	contraindicate	smoked	cannabis,	or	gastric	problems	that	delay	oral	absorption.
CURRENT MEDICINAL CANNABIS LEGISLATION IN AUSTRALIA
The	Narcotic	Drugs	Amendment	Bill	2016	(Cth)	facilitates	the	production	of	medicinal	cannabis	products	
for	specified	patients	under	clinical	care	in	Australia.	Access	to	any	cannabis	products	manufactured	under	




This means medicinal cannabis is available for clinical care, with restriction on the cultivation, manufacturing, 
supply, distribution, possession and use to reduce abuse and misuse.  At the time of writing, both Poisons and 
Therapeutic	Goods	Amendment	(Designated	Non‑ARTG	Products)	Regulation	2016	in	New	South	Wales	and	
Access	to	Medicinal	Cannabis	Act	2016	in	Victoria	allow	restricted	access	to	medicinal	cannabis	produced	
under this national licensing scheme once it becomes available. Other states and territories are currently in 
the process of developing legislation and schemes covering restricted access. 
The position of Australian nurses caring for patients on medicinal cannabis treatment
The principle of palliative care is to improve the quality of life of patients living with life‑limiting conditions 
based on the best evidence available (World Health Organization 2015). Although some evidence suggests 
cannabis‑based	drugs,	including	dronabinol	and	nabilone,	may	have	therapeutic	benefits	for	some	patients	
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with	life‑limiting	conditions	(Philipsen	et	al	2014;	Green	and	De‑Vries	2010),	medicinal	cannabis	in	emesis	
control is a very new treatment option available for Australians. In principle, nurses should act lawfully and 
comply	with	the	professional	standards	as	set	out	by	the	Nursing	and	Midwifery	Board	of	Australia	when	
caring for patients with life‑limiting conditions who are using or want to use cannabis as a treatment modality 
for symptom management. In addition, nurses should:




• be aware of and keep up‑to‑date with the changes in legislation and regulations in the medicinal use of 
cannabis.	The	regulations	may	be	changed	when	more	scientific	evidence	about	its	beneficial	medical	
effects	on	humans	becomes	available	in	the	near	future;




• respect and support the patients who have chosen to use cannabis for symptom management such 
as anti‑emesis (Philipsen et al 2014). 
CONCLUSION
Overall, in the context of palliative care, it is clear that patients with life‑limiting conditions should receive 
the optimal treatments in order to improve their quality of life. In comparison to conventional medications, 
the use of medicinal cannabis in emesis control is a new phenomenon in palliative care. The information 
available in relation to the long‑term therapeutic effects of cannabis and the contraindication with other drugs 
is very limited. Further research is required to explore the needs of patients who use medicinal cannabis for 
anti‑emesis and their experience in receiving cannabis treatment in Australia. 
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